Discolored, Tender Spots on Face and Ear

For the answer, click here.

Question 2:

NEXT QUESTION »

For the answer, click here.

Question 3:

NEXT QUESTION »

For the answer, click here.

Question 4:

NEXT QUESTION »

For the answer, click here.

Question 5:

ANSWER KEY »

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

ANSWER KEY:

Question 1. E

Question 2. A

Question 3. D

Question 4. H

Question 5. E

Related Content

More than Half of US Adults May Be Eligible for Semaglutide Therapy / image credit Dhruv Kazi, MD, MSc, MS Smith Center for Outcomes Research in Cardiology

November 21st 2024

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

August 30th 2023

Among Stroke Survivors, GLP-1RAs, SGLT2is May Reduce Risk of Future MI, Recurrent Stroke

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

November 11th 2024

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.

Patient Care Editorial Staff

October 29th 2020

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

November 1st 2024

October Issue of Patient Care Online Supplement is Now Live

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

October 14th 2024

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

Find details on challenges primary care clinicians face in treating older adults with T2D and an expert discussion on navigating treatments to delay T1D.

Related Content

November 21st 2024

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

August 30th 2023

Among Stroke Survivors, GLP-1RAs, SGLT2is May Reduce Risk of Future MI, Recurrent Stroke

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

November 11th 2024

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.

Patient Care Editorial Staff

October 29th 2020

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

November 1st 2024

October Issue of Patient Care Online Supplement is Now Live

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

October 14th 2024